Intra-cellular Therapies Stock News

Related Stocks: AMGN , NVAX , ITCI , SRPT , BGNE , GH , ALKS , AZN , CRBU , CRL , RLYB , BHVN , ALLK , BPMC , BBIO , IOVA , DCPH , REPL ,

NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ne

Intra-Cellular Therapies (NASDAQ:ITCI) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations. Valuation and Earnings This table compares Intra-Cellular Therapies and Precigens gross revenue, earnings per share (EPS) and []

Royal Bank of Canada increased its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 39.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,419 shares of the biopharmaceutical companys stock after buying an additional 5,492 shares during the period. []

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for the year-to-date peri

Autism spectrum disorder (ASD) is a neurological and developmental disorder that begins early in childhood and lasts throughout a person''s life. It affects how a person acts and interacts with others, communicates, and learns. It includes what used to be

Parametric Portfolio Associates LLC raised its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 101.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 235,871 shares of the biopharmaceutical companys stock after purchasing an additional 119,017 shares during the period. Parametric Portfolio []

Equities research analysts expect Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report sales of $24.02 million for the current quarter, according to Zacks. Three analysts have issued estimates for Intra-Cellular Therapies earnings, with estimates ranging from $23.05 million to $24.50 million. Intra-Cellular Therapies reported sales of $12.45 million during the same quarter last year, which would suggest []

AQR Capital Management LLC cut its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 53.7% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 8,522 shares of the biopharmaceutical companys stock after selling 9,872 shares during the quarter. AQR Capital Management LLCs holdings in Intra-Cellular Therapies were worth $348,000 at the end []

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) was the recipient of a large decrease in short interest in October. As of October 29th, there was short interest totalling 4,210,000 shares, a decrease of 21.2% from the October 14th total of 5,340,000 shares. Based on an average trading volume of 441,200 shares, the short-interest ratio is currently 9.5 days. []

Prudential Financial Inc. acquired a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 54,647 shares of the biopharmaceutical companys stock, valued at approximately $2,231,000. Prudential Financial Inc. owned 0.07% of Intra-Cellular Therapies as of []

Virtu Financial LLC acquired a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the 2nd quarter, HoldingsChannel.com reports. The fund acquired 9,780 shares of the biopharmaceutical companys stock, valued at approximately $399,000. A number of other institutional investors and hedge funds have also added to or reduced their stakes in ITCI. Janus Henderson Group PLC []

Amalgamated Bank increased its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 93.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,346 shares of the biopharmaceutical companys stock after purchasing an additional 6,441 shares during the quarter. Amalgamated Banks holdings in []

Intra-Cellular Therapies (NASDAQ:ITCI) had its target price boosted by Royal Bank of Canada from $48.00 to $50.00 in a research note published on Wednesday morning, Analyst Ratings Network reports. They currently have an outperform rating on the biopharmaceutical companys stock. Several other research firms have also recently weighed in on ITCI. Zacks Investment Research cut []

Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q3 2021 Results - Earnings Call Transcript